Overview Request Sample Pages Request Customization Download PDF
You are viewing: India Veterinary Monoclonal Antibodies Market analysis

The India Veterinary Monoclonal Antibodies Market was valued at $13.02 Million in 2025 and projected to reach to $21.79 Million by 2030, representing a compound annual growth rate of 10.9%. India's veterinary monoclonal antibodies market is positioned for significant expansion, driven by the convergence of agricultural modernization and increasing pet healthcare spending.

India Veterinary Monoclonal Antibodies Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Veterinary Monoclonal Antibodies Market Trends and Insights

  • India's market is driven by increasing livestock disease management, rising pet ownership in urban centers, and growing adoption of advanced immunotherapeutic solutions across the country.
  • The 10.9% compound annual growth rate reflects India's expanding veterinary healthcare infrastructure and heightened awareness of precision medicine in animal health. India's market expansion is supported by a large agricultural base, significant dairy and poultry sectors, and emerging companion animal care segments.
  • India's regulatory environment is gradually aligning with international standards, facilitating product approvals and market entry.
  • By 2030, India is expected to capture a meaningful share of Asia Pacific's veterinary monoclonal antibodies demand, driven by both preventive and therapeutic applications in livestock and companion animals..

Key Market Statistics

  • CAGR (2025-2030) 10.9% CAGR
  • Market Size, 2025 ~USD 13.02 Million
  • Forecast, 2030 ~USD 21.79 Million
  • Country India

India Veterinary Monoclonal Antibodies Market Overview

Market Valuation Growth :

India's veterinary monoclonal antibodies market is valued at USD 13.02 million in 2025, with projections reaching USD 21.79 million by 2030, representing a robust 10.9% CAGR.

Livestock Disease Management :

Increasing focus on livestock health and disease prevention across India's agricultural sector is driving demand for advanced immunotherapeutic solutions in veterinary care.

Urban Pet Ownership Surge :

Rising pet ownership in metropolitan areas like Mumbai, Delhi, and Bangalore is creating new market opportunities for premium veterinary monoclonal antibody treatments.

Immunotherapy Adoption :

Growing awareness and adoption of advanced immunotherapeutic solutions among Indian veterinary practitioners and animal healthcare facilities is accelerating market expansion.

India Veterinary Monoclonal Antibodies Market Dynamics

  • The country's large livestock population and growing middle-class pet owners create substantial demand for innovative immunotherapeutic treatments.
  • Government initiatives promoting animal health and disease control, combined with rising veterinary infrastructure investments, are expected to support sustained market growth through 2030. The 10.9% CAGR reflects India's unique market dynamics, where both commercial livestock operations and companion animal care are expanding simultaneously.
  • Increasing collaboration between Indian veterinary institutions and global biotech companies, along with improved regulatory pathways for monoclonal antibody approvals, will further accelerate market penetration and product availability across urban and rural veterinary practices..

Related Ecosystem

Animal Health

Top Technologies
  • Polymerase Chain Reaction (PCR) Tests
  • Porcine
  • Immunodiagnostics
  • Lateral Flow Assays
  • Microarrays
Top Companies
  • Zoetis Inc.
  • Patterson Companies, Inc.
  • Virbac
  • Elanco Animal Health Incorporated
  • BOEHRINGER INGELHEIM GMBH

    Key Takeaways

    • India's veterinary monoclonal antibodies market is valued at USD 13.02 million in 2025 and will reach USD 21.79 million by 2030, representing a 10.9% CAGR.
    • India's large livestock sector and growing companion animal care market are primary growth catalysts for monoclonal antibody adoption.
    • India's improving regulatory framework and veterinary infrastructure are accelerating product development and market penetration.
    • India's market is positioned as a key growth engine within the Asia Pacific region for veterinary immunotherapeutics.

    Veterinary Monoclonal Antibodies Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment BEDINVETMAB (LIBRELA) (Product)
    Forecast Period 2025-2030
    Growth Rate CAGR of 12.4% from 2025 to 2030
    Largest Segment SUBCUTANEOUS ROUTE OF ADMINISTRATION (Route Of Administration)
    Market Size Base Year (Billions) ~USD 1.71 (2025)
    Revenue Forecast (Billions) ~USD 3.06 (2030)
    Segments Covered Animal Type, Product, Route Of Administration, Therapy Area, End User, Animal Type 2023-2030

    India Veterinary Monoclonal Antibodies Market Report Segmentation

    6 segment dimensions are covered across the global market.

    By Animal Type

    • Canines
    • Felines
    • Other Animal Types
    • Other Animals

    By Product

    • Bedinvetmab (Librela)
    • Canine Parvovirus Monoclonal Antibody (Cpma)
    • Frunevetmab (Solensia)
    • Gilvetmab
    • Lokivetmab (Cytopoint)
    • Other Products

    By Route Of Administration

    • Intravenous (Iv) Route Of Administration
    • Intravenous Route Of Administration
    • Oral Route Of Administration
    • Subcutaneous (Sc) Route Of Administration
    • Subcutaneous Route Of Administration

    By Therapy Area

    • Dermatology
    • Infectious Diseases
    • Oncology
    • Other Therapy Areas
    • Pain Management

    By End User

    • Other End Users
    • Veterinary Clinics
    • Veterinary Hospitals/ Specialty Centers
    • Veterinary Hospitals/Specialty Clinics
    • Veterinary Research & Academic Institutes

    By Animal Type 2023-2030

    • Canines
    • Felines
    • Other Animals

    INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030

    Segment2023202420252026202820292030CAGR (%)
    OTHER END USERS0.981.051.131.211.391.51.617.4
    VETERINARY CLINICS4.184.675.215.827.268.129.111.8
    VETERINARY HOSPITALS/SPECIALTY CLINICS5.115.646.246.98.469.3810.4110.8
    VETERINARY RESEARCH & ACADEMIC INSTITUTES0.880.951.041.141.361.491.639.3
    TOTAL11.1512.3113.6115.0618.4820.4922.7510.8

    Target Audience

    • Veterinary Pharmaceutical Companies : Manufacturers and distributors need India-specific market data to assess market entry opportunities, competitive positioning, and revenue forecasting for monoclonal antibody product launches.
    • Livestock & Dairy Industry Players : Large-scale livestock operators and dairy companies require insights into disease management solutions and immunotherapy adoption to optimize herd health and productivity investments.
    • Veterinary Clinics & Hospitals : Private and institutional veterinary practitioners need market intelligence on emerging treatment options and adoption trends to enhance service offerings and clinical capabilities.
    • Investment & Private Equity Firms : Investors evaluating opportunities in India's animal healthcare sector need comprehensive market sizing, growth projections, and competitive analysis for portfolio decision-making.
    • Government & Regulatory Bodies : Agricultural and health ministry officials require market data to inform policy decisions, regulatory frameworks, and public health initiatives related to animal disease management.

    Reasons to Buy this Report

    • India-Specific Market Sizing : Access precise valuation data for India's veterinary monoclonal antibodies market with country-level forecasts through 2030, enabling accurate business planning and investment decisions.
    • Livestock & Pet Segment Insights : Understand the dual-market dynamics of India's livestock disease management and urban pet ownership trends, identifying growth opportunities across both commercial and companion animal segments.
    • Competitive Landscape Analysis : Gain detailed intelligence on India-specific competitive positioning, local veterinary practices adoption rates, and regulatory environment affecting monoclonal antibody market entry.
    • Growth Driver Identification : Identify key catalysts driving India's 10.9% CAGR, including government animal health initiatives, veterinary infrastructure development, and emerging immunotherapy adoption patterns.
    • Strategic Market Entry Planning : Develop targeted go-to-market strategies for India with actionable insights on distribution channels, pricing dynamics, and customer segments across metropolitan and rural veterinary markets.

    Frequently asked questions

    What is the current size of India's veterinary monoclonal antibodies market?

    India's veterinary monoclonal antibodies market is valued at USD 13.02 million in 2025 and is expected to grow to USD 21.79 million by 2030.

    What is the projected growth rate for India's veterinary monoclonal antibodies market?

    India's market is projected to grow at a compound annual growth rate (CAGR) of 10.9% from 2025 to 2030.

    What are the main drivers of growth in India's veterinary monoclonal antibodies market?

    India's growth is driven by increasing livestock disease management, rising pet ownership in urban areas, expanding veterinary healthcare infrastructure, and growing adoption of advanced immunotherapeutic solutions.

    Which animal segments are driving India's veterinary monoclonal antibodies market?

    India's market is driven by both livestock segments (dairy, poultry) and the emerging companion animal care sector, with both contributing significantly to market expansion.

    How does India's market compare to the global veterinary monoclonal antibodies market?

    India's market is growing at 10.9% CAGR, slightly below the global CAGR of 12.4%, but represents a key growth opportunity within the Asia Pacific region.

    RESEARCH METHODOLOGY

    This study involved the extensive use of both primary and secondary sources. The research process involved evaluating various factors affecting the industry to identify the segmentation, industry trends, key players, competitive landscape, market dynamics, and growth strategies.

    Secondary Research

    In the secondary research process, various secondary sources were referred to, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect valuable information for an extensive, technical, market-oriented, and commercial study of the veterinary monoclonal antibodies market. It was also used to obtain information about the key players, market classification & segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various primary sources from the supply and demand sides were interviewed to obtain critical qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, vice presidents, chairpersons, chief executive officers, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary monoclonal antibodies market. Primary sources from the demand side include professionals from veterinary hospitals and clinics, academic & research institutes, and pet owners.

    Breakdown of primary interviews

    Veterinary Monoclonal Antibodies Market

    Note: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

    Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The total size of the veterinary monoclonal antibodies market was determined after data triangulation from two approaches, as mentioned below. After each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.

    Veterinary Monoclonal Antibodies Market

    Data Triangulation

    After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

    Market Definition

    Veterinary monoclonal antibodies are laboratory-produced antibodies designed to target specific antigens in animals, offering precise treatment for conditions like atopic dermatitis, osteoarthritis, and infectious diseases. These species-specific biologics are engineered to work effectively in the immune systems of dogs, cats, or livestock. They represent a significant advancement over traditional drugs by providing targeted therapy with fewer side effects.

    Stakeholders

    • Veterinary monoclonal antibody manufacturers
    • Animal healthcare product manufacturers
    • Veterinary monoclonal antibody distributors and wholesalers
    • Animal welfare associations
    • Veterinary clinics and care centers
    • Research and consulting firms
    • Veterinary R&D organizations
    • Contract research organizations
    • Contract manufacturing organizations
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the veterinary monoclonal antibodies market by animal type, product, therapy area, route of administration, end user, and region
    • To identify and analyze key drivers, restraints, opportunities, and challenges influencing market growth
    • To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis, patent analysis, impact of AI, case study analysis, adjacent market analysis, unmet needs/end user expectations, and trends and disruptions impacting customer business in the market
    • To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze opportunities for stakeholders and provide details of the competitive landscape for key players
    • To strategically profile key players in this market and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as product launches and approvals, partnerships, and expansions in the market

    Get the Full Veterinary Monoclonal Antibodies Market Report

    Full forecast, segment splits, and company analysis for all Veterinary Monoclonal Antibodies Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status